Topic: ERK1/2 phosphorylation

The melanocortin receptor subtype 4 (MC4R) is expressed in various human cells such as skin melanocytes, astrocytes, and neural progenitor cells1.Our aim is to evaluate the role of MCR4 as a novel target in melanoma therapy, using a selective antagonist ML00253764 (ML) alone and in combination with the B-Raf V600E inhibitor Vemurafenib.We employed the human melanoma B-Raf mutated A-2058 and WM 266-4 cell lines, while the CRISPR/Cas9 system was used to eliminate the MCR4 gene in the A-2058 cell line (MCR4 null).MC4R protein expression in melanoma cells was then tested though immunohistochemistr

Depression, affecting 280 million people worldwide, is marked by a significant treatment gap. Current therapies with delayed onset of action fail to alleviate the symptoms in almost half of patients, often neglecting the cognitive deficits. This highlights the critical need for fast-acting antidepressants with memory-enhancing properties. HBK-15, a multimodal compound, previously demonstrated antidepressant-, anxiolytic-like and antiamnesic effects in rodents. Our study aimed to explore HBK-15's potential in reversing stress-induced behavioral abnormalities and elucidating its underlying mecha